[{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","commit":"d1f1037d6e","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on thirty more companies","file":"src/data/supporting.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.glpg.com\" }]"}]},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/supporting.ts","type":"changed","fields":[{"field":"tldr","before":"\"Biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; restructured its cell-therapy business in 2025.\"","after":"\"Galapagos is a biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; it restructured its cell-therapy business in 2025.\""}]},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","commit":"6d26880f6f","date":"2026-09-08","author":"Jude Gomila","message":"Add supporting technologies, infrastructure companies, and regulatory-science terms","file":"src/data/supporting.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"technologies"}]}]